Nuvectis Pharma, Inc. Operating Cash Flow
Nuvectis Pharma, Inc. (NVCT) reported Operating Cash Flow of -$11.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.53M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$6.51M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.97M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.49M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$16.01M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$12.25M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$15.95M.
- Nuvectis Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$13.56M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$11.04M 10-Q · filed 2026-08-04 | -$15.02M derived: sum of 3 quarters · filed 2026-08-04 | -$19.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$6.51M 10-Q · filed 2026-05-05 | -$10.48M derived: sum of 2 quarters · filed 2026-05-05 | -$14.98M derived: sum of 3 quarters · filed 2026-05-05 | -$18.35M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$8.47M derived: sum of 2 quarters · filed 2026-02-11 | -$11.84M derived: sum of 3 quarters · filed 2026-08-04 | -$16.01M 10-K · filed 2026-02-11 |
| 2025-09-30 | -$4.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$7.86M derived: sum of 2 quarters · filed 2026-08-04 | -$12.04M 10-Q · filed 2025-11-04 | -$14.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$7.54M 10-Q · filed 2026-08-04 | -$10.01M derived: sum of 3 quarters · filed 2026-08-04 | -$12.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$4.17M 10-Q · filed 2026-05-05 | -$6.64M derived: sum of 2 quarters · filed 2026-05-05 | -$9.04M derived: sum of 3 quarters · filed 2026-05-05 | -$12.06M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$4.87M derived: sum of 2 quarters · filed 2026-02-11 | -$7.89M derived: sum of 3 quarters · filed 2026-02-11 | -$12.25M 10-K · filed 2026-02-11 |
| 2024-09-30 | -$2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$5.42M derived: sum of 2 quarters · filed 2025-11-04 | -$9.78M 10-Q · filed 2025-11-04 | -$13.63M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$7.38M 10-Q · filed 2025-08-05 | -$11.23M derived: sum of 3 quarters · filed 2025-08-05 | -$14.47M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$4.36M 10-Q · filed 2025-05-06 | -$8.21M derived: sum of 2 quarters · filed 2025-05-06 | -$11.45M derived: sum of 3 quarters · filed 2025-05-06 | -$15.54M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$7.09M derived: sum of 2 quarters · filed 2025-02-25 | -$11.18M derived: sum of 3 quarters · filed 2025-02-25 | -$15.95M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$3.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$7.33M derived: sum of 2 quarters · filed 2024-11-05 | -$12.10M 10-Q · filed 2024-11-05 | -$15.62M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$8.86M 10-Q · filed 2024-08-06 | -$12.38M derived: sum of 3 quarters · filed 2024-08-06 | -$16.80M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$4.78M 10-Q · filed 2024-05-07 | -$8.29M derived: sum of 2 quarters · filed 2024-05-07 | -$12.72M derived: sum of 3 quarters · filed 2024-05-07 | -$15.26M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$7.94M derived: sum of 2 quarters · filed 2024-03-05 | -$10.48M derived: sum of 3 quarters · filed 2024-03-05 | -$13.56M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$6.97M derived: sum of 2 quarters · filed 2023-11-08 | -$10.04M 10-Q · filed 2023-11-08 | -$11.11M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$5.62M 10-Q · filed 2023-08-09 | -$6.69M derived: sum of 3 quarters · filed 2023-08-09 | -$11.11M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$3.08M 10-Q · filed 2023-05-10 | -$4.14M derived: sum of 2 quarters · filed 2023-05-10 | -$8.57M derived: sum of 3 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$5.49M derived: sum of 2 quarters · filed 2023-03-08 | -$9.50M 10-K · filed 2023-03-08 | |
| 2021-09-30 | -$4.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$8.44M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$4.01M 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |